NEW YORK (GenomeWeb) – Diagnostics company InterVenn BioSciences said today it has raised $9.4 million in a funding round led by Genoa Ventures.

The Redwood City, California-based firm will use the funds to develop its lead product, a mass spectrometry-based blood test for ovarian cancer. The company said it is currently doing analytical and clinical validation for the test, which it ultimately plans to offer as a laboratory-developed test.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.